Publication | Closed Access

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

Tumor ImmunologySolid TumorsDendritic CellMedicineAutologous Tumor LysateImmunologyVaccine TrialTherapeutic VaccineVaccine DesignImmunotherapyPrecision VaccinologyRadiation Oncology